Jeppe Krog Rasmussen, Louise Conradsen, and Morten Martinsen welcomed the Ministry of Foreign Affairs along with the rest of the DanCann Pharma team to their facility in Jutland. The purpose of the visit was to exchange knowledge about exports and investments within Europe regarding medicinal cannabis, and to showcase their production facility Biotech Pharm1 ("BP1").

[image]

DanCann Pharma was established in 2018 and has since then taken significant steps towards establishing itself as a producer and distributor of medicinal cannabis. Back in November, DanCann Pharma became EU-GMP certified for the production of medicinal cannabis, and they have already entered into export agreements for the first productions in 2023 and 2024. The demand for their quality assured products with high THC content is significant, and therefore, collaboration with the Ministry of Foreign Affairs' export advice makes good sense.

During the meeting, there was naturally a significant focus on the Czech market as a potential sales opportunity. Information and knowledge were shared about how to penetrate the market, and exciting topics were discussed in terms of the cooperation section with local companies and the future.

Louise Conradsen states:

"We can benefit from having advice on exports and investments close to us to become more informed about the various regulatory requirements that exist in Europe within medicinal cannabis. Running a startup company requires constant monitoring of the market and capital, and I believe that we can benefit greatly from the resources offered. We look forward to closer collaboration in the future."

[image]

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.

The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (OTCQB: DCPXF).

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Phone: +45 2963 6920

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.